Most Recent Articles about Assembly Biosciences
Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates http://www.zacks.com/stock/news/336439/assembly-biosciences-asmb-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-336439 Nov 08, 2018 - Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/333438/analysts-estimate-assembly-biosciences-asmb-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-333438 Oct 31, 2018 - Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade http://feeds.benzinga.com/~r/benzinga/~3/luY90gjuCRE/recent-assembly-biosciences-weakness-provides-attractiv Oct 08, 2018 -

Assembly Biosciences Inc (NASDAQ: ASMB) shares have shed over one-fourth of their value since late September, creating an opportunity to buy the dip, B. Riley FBR said Monday. 

Related Companies

Name Exchange Price Mkt Cap
RCKT Rocket Pharmaceuticals, Inc. NASDAQ $22.24 $882.06M
RVNC Revance Therapeutics, Inc. NASDAQ $23.5001 $868.04M
AMPH Amphastar Pharmaceuticals, Inc. NASDAQ $18.33 $847.88M
AMRN Amarin Corporation plc NASDAQ $2.83 $838.67M
CTMX CytomX Therapeutics, Inc. NASDAQ $18.52 $832.73M
Sector: Health Care > Industry: Major Pharmaceuticals